Longeveron

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to slow the effects of life-threatening and chronic aging-related conditions using cellular therapies, is making inroads with Lomecel-B™, its investigational treatment for hypoplastic left heart syndrome (HLHS), Alzheimer...

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress. The company just reported positive top-line results from its phase 2a trial of Lomecel-B™, its...

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress. The company just reported positive top-line results from its phase 2a trial of Lomecel-B™, its...

Nations all over the world are getting older, but Japan is leading the charge, with nearly a third of its total population over 65 — making Japan the oldest society in the world.  While longer lifespans are great news, the growing number of seniors is bringing increased attention to the...

Wa’el Hashad, CEO of Longeveron (NASDAQ: LGVN), was a guest recently on Benzinga’s All-Access. Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead investigational product is Lomecel-B™,...

Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat. One is hypoplastic left heart...

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months. Longeveron’s primary drug candidate, a cell-based...

Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga. Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead investigational product, Lomecel-B, is derived from culture-...

Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Longeveron’s primary drug is  Lomecel-B™, which is being developed as a potential therapy for Alzheimer's disease, Aging-Frailty,...

Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN) Lomecel-B. The drug candidate showed a 100% survival rate after 5 years in its ELPIS I trial,...

Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. The Company, which is now conducting its phase 2a trial, is a clinical-stage biotechnology firm working to develop...

Longeveron Inc. (NASDAQ: LGVN) announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll 45 patients and its primary objective is to evaluate safety.  “We are excited to...

We are maintaining our Buy rating and $20 (peak sales-based) price target on Longeveron (NASDAQ: LGVN). The company reported 2Q results on Friday, with 2Q operating expenses of $4.4M versus our $5.4M estimate. 2Q revenue of $0.5M exceeded our $0.2M estimate, on higher clinical trial revenue...

According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. The rising number of clinical studies for cell-based therapies and investments in the industry...

Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN) peer-reviewed study in the Journal of the Alzheimer’s Association is a significant step for the company. The “Phase 1 Trial Results of its Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia” for...